Falk Gastro Info 11/2017

Video

Always keep in mind the drug-induced risk of infection with inflammatory bowel diseases

Video report presented by Dr. Eugeni Domènech, Badalona, Spain at the Symposium 206 “From the New and Complex Concepts to the Real Patient: Science and Clinic in IBD”, March 31 – April 1, 2017 in Madrid, Spain.
© 2017 Falk Foundation e.V., Freiburg. All rights reserved.

Summary

Certain therapeutic agents for IBD can increase the risk of infection. This particularly applies to systemic corticosteroids and biologics. In addition to the general risk of infection, the risk of serious infections also increases significantly under therapy. Treatment with mesalazine as well as with antibiotics is unproblematic in this regard, apart from the risk of infection with Clostridium difficile.

Please switch on your loudspeakers!

Link to Falk Mediacenter

Latest research in brief:

Bowel

Text:

Overman MJ et al, Lancet Oncol. 2017;18(9):1182–91

Immune therapy for colorectal carcinoma: The PD-1 checkpoint inhibitor nivolumab provided durable responses and disease control in a proof-of-principle study in pre-treated patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal carcinoma.

Link to text

Text:

Sands BE et al, Gastroenterology. 2017;153(1):77–86.e6

Therapy of patients with moderate to severe Crohn’s disease with previous failure of TNF inhibitors: This phase 2a study demonstrates clinical improvement following therapy with the monoclonal antibody MEDI2070 targeting IL-23.

Link to text

Text:

Roblin X et al, Aliment Pharmacol Ther. 2017;46(2):142–9

Azathioprine dose reduction in patients with inflammatory bowel disease and combination therapy with infliximab: Azathioprine dose reduction (1–1.25 mg/kg or 6-TGN concentrations > 105 pmol/8 x 108 RBC) but not withdrawal appears to be as effective as continuation of azathioprine at full dose.

Link to text

Liver Biliary Tracts

Text:

Ayonrinde OT et al, J Hepatol. 2017;67(3):568–76

Non-alcoholic fatty liver disease (NAFLD) in adolescents: Breastfeeding for at least 6 months, avoidance of early supplementary formula milk feeding, and normal maternal pre-pregnancy body mass index (BMI) may reduce the risk for NAFLD diagnosis during adolescence.

Link to text

Text:

Gane E et al, N Engl J Med. 2017;377(15):1448–55

Hepatitis C in patients with severe renal impairment: Antiviral treatment with glecaprevir and pibrentasvir for 12 weeks results in a high rate (98%) of sustained virological response in patients with stage 4 or 5 chronic kidney disease (with or without dialysis) and HCV genotypes 1–6.

Link to text

Text:

Fung J et al, Hepatology. 2017;66(4):1036–44

Hepatitis B after liver transplantation: A current study confirms that long-term prophylaxis with entecavir only is highly effective at preventing HBV reactivation after liver transplantation. At 8 years post-transplant, 92% of patients were negative for HBsAg and 100% were negative for HBV DNA.

Link to text

Oesophagus Stomach Duodenum

Text:

Hsu PI et al, Am J Gastroenterol. 2017;112(9):1374–81

Eradication of Helicobacter pylori: Ten-day quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline and levofloxacin is more effective than standard levofloxacin triple therapy in the second-line treatment.

Link to text

Text:

Klatte DCF et al, Gastroenterology. 2017;153(3):702–10

Side effects of proton pump inhibitor (PPI) therapy: compared to H2-blocker therapy, PPI therapy correlates with a modestly increased risk for progression of chronic kidney disease.

Link to text

Text:

Chan FKL et al, Lancet. 2017;389(10087):2375–82

Gastrointestinal safety of high-risk patients requiring aspirin and NSAID therapy: Compared to naproxen, celecoxib therapy is associated with fewer gastrointestinal bleeding events.

Link to text

Pancreas

Text:

Kirkegård J et al, Am J Gastroenterol. 2017;112(9):1366–72

Cancer risk and chronic pancreatitis: metaanalysis indicates that patients with chronic pancreatitis have an approx. 8-fold increased risk to develop pancreatic cancer.

Link to text

International Symposia and Workshops

Workshop

Workshop on Oral, Gastrointestinal and Pulmonary GvHD

November 17 – 18, 2017, Regensburg, Germany
University Hospital Regensburg, Großer Hörsaal, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany

Program

Registration

Online registration

Workshop

Liver-Gut-Microbiome Interactions

January 25 – 26, 2018, Hamburg, Germany
Radisson Blu Hotel, Marseiller Str. 2, 20355 Hamburg, Germany

Program